Clinical Study
Effectiveness and Safety of Concurrent Use of First-Line Antiretroviral and Antituberculous Drugs in Rwanda
Table 1
Patients’ baseline values.
| | Variable | | HIV | HIV/TB |
| | Gender | Male | 19 (31.7%) | 26 (43.3%) | | Female | 41 (68.3%) | 34 (56.7%) |
| | Age (years) | <40 | 43 (71.7%) | 53 (88.3%) | | >40 | 17 (28.3%) | 7 (11.7%) | | Median | 30 (27–46) | 30 (24–33) | | IQR | 21.5 | 9.8 |
| | Weight (kg) | <50 | 17 (28.3%) | 22 (36.7%) | | >50 | 43 (71.7%) | 38 (63.3%) | | Median | 54 (47–58) | 52 (44–58) | | IQR | 12 | 13.5 |
| | CD4 cells/mm3 | <200 | 60 (100%) | 50 (83.3%) | | >200 | 0 (0.0%) | 10 (16.7%) | | Median | 78 (53–117) | 100 (70–180) | | IQR | 64 | 109.8 |
|
|
Median values (25th–75th percentiles).
|
